| 1 | 14614022 | Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. | Clin Cancer Res | 2003 Nov 1 |
3 |
| 2 | 16809434 | Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma. | FASEB J | 2006 Aug |
2 |
| 3 | 17714938 | Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis. | Eur J Cancer | 2007 Sep |
3 |
| 4 | 19212692 | Pharmacological inhibition of poly(ADP-ribose) polymerase activity down-regulates the expression of syndecan-4 and Id-1 in endothelial cells. | Int J Oncol | 2009 Mar |
1 |
| 5 | 20464779 | Pharmacological inhibition of poly(ADP-ribose) polymerase (PARP) activity in PARP-1 silenced tumour cells increases chemosensitivity to temozolomide and to a N3-adenine selective methylating agent. | Curr Cancer Drug Targets | 2010 Jun |
4 |
| 6 | 22640737 | Inhibition of poly(ADP-ribose) polymerase inhibits ischemia/reperfusion induced neurodegeneration in retina via suppression of endoplasmic reticulum stress. | Biochem Biophys Res Commun | 2012 Jun 29 |
10 |